OAR Logo
bg banner board of directors

OAR Mission and Structure

To foster education, communication, and shared expertise to provide timely and innovative solutions to challenges impacting safe and effective orthopaedic treatment delivery to patients.

Convened by the Orthopaedic Surgical Manufacturers Association (OSMA), OAR establishes a structured forum for cross stakeholder engagement. The structure includes a steering committee with representatives from each constituent group, working groups aligned with strategic priorities, and broader think tank sessions open to all interested stakeholders within the orthopedic community. 

Key Stakeholders

Clinical Community

Research Community

Standards Community

Industry

Patient Advocacy Groups

Regulatory Agencies

FDA Collaborative Community Designation

Since July 2022 , OAR has been provisionally approved by FDA as a CDRH collaborative community. An executed charter, reflecting current leadership, will be submitted to FDA to achieve full collaborative community designation.

FDA collaborative community status would establish it as the first and only orthopaedics-focused collaborative community within FDA’s Center for Devices and Radiological Health (CDRH), widening the footprint for broader engagement throughout the orthopaedic ecosystem. There are currently fewer than 20 formally designated collaborative communities.

img fda collborative community

What is an FDA Collaborative Community?

img collab community

A collaborative community is a continuing forum in which private- and public-sector members, which can include the FDA, work together on medical device challenges to achieve common objectives and outcomes. They are convened by interested stakeholders and may exist indefinitely, produce deliverables as needed, and tackle challenges with broad impacts. Collaborative communities may develop for a number of reasons, including when: 

OAR Value Proposition

ic cross stakeholder communication

Cross-Stakeholder Communication and FDA Collaboration

ic standards development

Standards Development for New/Emerging Technologies

ic patient access

Patient Access to Custom and Compassionate Use Devices

ic expanded use of real world evidence

Expanded Use of Real World Evidence and Registries

ic orthopaedic research

Orthopaedic Research Data Analysis and Standardization

ic reimbursement strategies

Reimbursement Strategies

ic additional opportunities

Additional Opportunities

ic cross stakeholder communication

Cross-Stakeholder Communication and FDA Collaboration

OAR serves as the only orthopaedics-focused forum uniting all six key stakeholder groups, providing:

ic standards development

Standards Development for New and Emerging Technologies

OAR could serve as a forum for:

ic patient access

Patient Access to Custom and Compassionate Use Devices

OAR can play a role in:

ic expanded use of real world evidence

Expanded Use of Real World Evidence and Registries

The orthopaedic community recognizes the tremendous value in existing device data. The key challenge is determining how to harness this information effectively without compromising regulatory decision-making rigor. A multi-stakeholder approach could address:

ic orthopaedic research

Orthopaedic Research Data Analysis and Standardization

OAR recognizes the importance of data analysis for understanding the burden of musculoskeletal disease and improving patient care. ORS’s pillars of data-driven advocacy and education align well with OAR’s mission. 

Specific opportunities include:

ic reimbursement strategies

Reimbursement Strategies

OAR provides a cross collaborative framework to improve patient outcomes by supporting providers and patients, particularly in areas of bone health and secondary fracture prevention. 

ic additional opportunities

Additional Opportunities

OAR participation provides: